Evidence-based prescribing of diabetes medications: are we getting closer?,The Lancet Diabetes & Endocrinology

当前位置： X-MOL 学术 › Lancet Diabetes Endocrinol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Evidence-based prescribing of diabetes medications: are we getting closer?
The Lancet Diabetes & Endocrinology ( IF 44.0 ) Pub Date : 2020-01-29 , DOI: 10.1016/s2213-8587(20)30020-6
Srikanth Bellary ₁ , Abd A Tahrani ₂ , Anthony H Barnett ₃

Affiliation

The cardiovascular safety of glucose-lowering drugs came under particular scrutiny in 2007, following the publication of a meta-analysis reporting possible adverse cardiovascular disease outcomes with rosiglitazone and concerns arising from large epidemiological studies. This finding led to new requirements from licensing authorities that all new type 2 diabetes therapies should show cardiovascular safety. ^,

中文翻译：